Compare FONR & MCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FONR | MCN |
|---|---|---|
| Founded | 1978 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.8M | 125.2M |
| IPO Year | 1995 | N/A |
| Metric | FONR | MCN |
|---|---|---|
| Price | $18.38 | $5.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 50.8K | ★ 56.7K |
| Earning Date | 02-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.96% |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | ★ $104,351,318.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.90 | ★ N/A |
| Revenue Growth | ★ 1.43 | N/A |
| 52 Week Low | $12.00 | $5.16 |
| 52 Week High | $18.86 | $6.39 |
| Indicator | FONR | MCN |
|---|---|---|
| Relative Strength Index (RSI) | 46.71 | 30.06 |
| Support Level | $18.31 | $5.65 |
| Resistance Level | $18.65 | $6.17 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 31.67 | 0.00 |
Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic imaging centers, which generates a vast majority of the revenue.
XAI Madison Equity Premium Income Fund is an investment management company. The Fund invests in an actively managed equity portfolio comprised of individual stocks and covered call options. The Fund's primary investment objective is to provide high level of current income and gains, with a secondary objective of capital appreciation.